Nishant Tageja

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

Neha Korde, Mark Roschewski, Adriana Zingone et al. · JAMA Oncology · 2015 · 308 citations · Full text

Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases

Prashant Tembhare, Constance M. Yuan, David Venzon et al. · Leukemia Research · 2013 · 95 citations

Hematological Malignancy, Bone Marrow Failure, Health Sciences +13

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma

Sham Mailankody, Dickran Kazandjian, Neha Korde et al. · Blood Advances · 2017 · 43 citations · Full text

Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients

Neha Korde, Adriana Zingone, Mary Kwok et al. · Blood · 2013 · 40 citations

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma

Dickran Kazandjian, Elizabeth Hill, Alexander Dew et al. · JAMA Oncology · 2021 · 38 citations · Full text